Insignis Therapeutics Receives FDA Fast Track Designation for IN-001 for Anaphylaxis Treatment
August 13, 2024 07:30 ET
|
Insignis Therapeutics, Inc.
Insignis’ liquid epinephrine sublingual spray for anaphylaxis, stable and usable under both extreme heat and cold, gains FDA Fast Track designation.
ARS Pharmaceuticals Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
May 10, 2023 12:02 ET
|
Block & Leviton LLP
BOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Block & Leviton is investigating ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) for potential securities law violations. Investors who have lost money in their...